Auriga Maintains Positive Stance On United Therapeutics (UTHR) Citing Strong Tyvaso Uptake
Tweet Send to a Friend
Auriga reiterates their Buy rating and $70 price target on United Therapeutics (Nasdaq: UTHR), saying the Tyvaso uptake looks strong.
This article: 110 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This article: 110 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
